PMV Pharma Q1 2024 Earnings Report
Key Takeaways
PMV Pharma reported first quarter financial results, highlighting the dosing of the first patient in the Phase 2 portion of the PYNNACLE trial and a cash, cash equivalents, and marketable securities balance of $213.1 million as of March 31, 2024.
First patient dosed in Phase 2 portion of the PYNNACLE trial assessing rezatapopt as monotherapy.
Phase 1 data of rezatapopt in advanced ovarian cancer featured at the 2024 SGO Annual Meeting on Women’s Cancer.
Cash, cash equivalents, and marketable securities totaled $213.1 million as of March 31, 2024, providing an expected cash runway to the end of 2026.
Net loss for the quarter ended March 31, 2024, was $15.3 million.
PMV Pharma
PMV Pharma
Forward Guidance
The company provided forward-looking statements regarding their future plans and expectations for rezatapopt, including the ability to obtain approval as a treatment option and the timing and success of the Phase 2 portion of the current clinical trial.